85 related articles for article (PubMed ID: 2935655)
1. Suppression of natural cytotoxicity in tumor-bearing mice and inhibition of the suppression by D-mannose.
Tanino T; Egawa K
Jpn J Exp Med; 1985 Aug; 55(4):155-60. PubMed ID: 2935655
[TBL] [Abstract][Full Text] [Related]
2. Suppression and abrogation of suppression of induced nonspecific cytotoxicity against tumor cells.
Egawa K; Tanino T
Jpn J Exp Med; 1985 Aug; 55(4):143-53. PubMed ID: 2935654
[TBL] [Abstract][Full Text] [Related]
3. T cell-dependent nonspecific cytotoxicity induced by culture of mouse spleen cells against natural killer-insensitive tumor cells.
Kiyohara T; Tanino T; Egawa K
Jpn J Exp Med; 1982 Aug; 52(4):201-8. PubMed ID: 7176145
[TBL] [Abstract][Full Text] [Related]
4. Modification of host antitumor defense mechanisms in mice by progressively growing tumor.
Maccubbin DL; Mace KF; Ehrke MJ; Mihich E
Cancer Res; 1989 Aug; 49(15):4216-24. PubMed ID: 2525950
[TBL] [Abstract][Full Text] [Related]
5. Tumor-specific suppressor T-cells which inhibit the in vitro generation of cytolytic T-cells from immune and early tumor-bearing host spleens.
Bear HD
Cancer Res; 1986 Apr; 46(4 Pt 1):1805-12. PubMed ID: 2936451
[TBL] [Abstract][Full Text] [Related]
6. Characterization of effector cells mediating antitumor activity in spleen cells of tumor-bearing mice.
Fuyama S; Yamamoto H; Arai S
Cancer Res; 1985 Sep; 45(9):4103-8. PubMed ID: 3875404
[TBL] [Abstract][Full Text] [Related]
7. Suppression of in vitro maintenance and interferon-mediated augmentation of natural killer cell activity by adherent peritoneal cells from normal mice.
Brunda MJ; Taramelli D; Holden HT; Varesio L
J Immunol; 1983 Apr; 130(4):1974-9. PubMed ID: 6187831
[TBL] [Abstract][Full Text] [Related]
8. Rapid killing of actinomycin D-treated tumor cells by human mononuclear cells. I. Effectors belong to the monocyte-macrophage lineage.
Colotta F; Peri G; Villa A; Mantovani A
J Immunol; 1984 Feb; 132(2):936-44. PubMed ID: 6690624
[TBL] [Abstract][Full Text] [Related]
9. Significance of suppressor macrophages for immunosurveillance of tumor-bearing mice.
Fujii T; Igarashi T; Kishimoto S
J Natl Cancer Inst; 1987 Mar; 78(3):509-17. PubMed ID: 2950265
[TBL] [Abstract][Full Text] [Related]
10. Influence of surgical removal and effect of levamisole on cytotoxic T-cell-mediated antitumor immunity in mice.
Gomi K; Morimoto M; Nomoto K
Cancer Res; 1983 Nov; 43(11):5120-5. PubMed ID: 6604572
[TBL] [Abstract][Full Text] [Related]
11. Suppression of the cytotoxic response of mouse lymphocytes to syngeneic tumor cells by tumor-promoting phorbol ester.
Fredrickson GG; Bennett M
Cancer Res; 1982 Sep; 42(9):3601-6. PubMed ID: 7105034
[TBL] [Abstract][Full Text] [Related]
12. Evidence for interaction between T cell populations of tumor-bearing and normal mice in immune suppression.
Ingenito GG; Calkins CE
J Immunol; 1981 Sep; 127(3):1236-40. PubMed ID: 6455472
[TBL] [Abstract][Full Text] [Related]
13. Production of colony-stimulating factor by tumor cells and the factor-mediated induction of suppressor cells.
Tsuchiya Y; Igarashi M; Suzuki R; Kumagai K
J Immunol; 1988 Jul; 141(2):699-708. PubMed ID: 2968407
[TBL] [Abstract][Full Text] [Related]
14. Some characteristics of the cyclophosphamide-induced immunopotentiating cells in the spleen of mice bearing a large MOPC-315 tumor.
Mokyr MB; Ye QW
Cancer Res; 1985 Oct; 45(10):4932-9. PubMed ID: 4027979
[TBL] [Abstract][Full Text] [Related]
15. Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production. Role of tumor-derived IL-10, TGF-beta, and prostaglandin E2.
Alleva DG; Burger CJ; Elgert KD
J Immunol; 1994 Aug; 153(4):1674-86. PubMed ID: 8046239
[TBL] [Abstract][Full Text] [Related]
16. Suppression of T cell cytotoxicity by nude mouse spleen cells: reversal by monosaccharides and interleukin 2.
Palladino MA; Ranges GE; Scheid MP; Oettgen HF
J Immunol; 1983 May; 130(5):2200-2. PubMed ID: 6220084
[TBL] [Abstract][Full Text] [Related]
17. Role of T-cells in the mechanism of reactivity of the microplate leukocyte adherence inhibition assay.
Raina S; Russo AJ; Jenkins D; Goldrosen MH
Cancer Res; 1981 Oct; 41(10):3950-5. PubMed ID: 6456811
[TBL] [Abstract][Full Text] [Related]
18. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
19. Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma.
Micallef MJ; Tanimoto T; Kohno K; Ikeda M; Kurimoto M
Cancer Res; 1997 Oct; 57(20):4557-63. PubMed ID: 9377569
[TBL] [Abstract][Full Text] [Related]
20. Nonspecific cytotoxic cells induced in vivo and their comparison to culture-induced cytotoxic cells.
Egawa K; Tanino T
Jpn J Exp Med; 1982 Oct; 52(5):237-42. PubMed ID: 7169668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
